BioCentury
ARTICLE | Company News

Mustang licenses immunodeficiency gene therapy from St. Jude

August 13, 2018 8:50 PM UTC

Mustang Bio Inc. (NASDAQ:MBIO) gained exclusive, worldwide rights to develop and commercialize an ex vivo lentiviral gene therapy to treat X-linked severe combined immunodeficiency (SCID) from St. Jude Children's Research Hospital.

St. Jude will receive an upfront payment and is eligible for milestones and royalties. Financial terms are undisclosed...